Immutep Ltd has released a press release.
Successful Meeting with FDA on Phase III Design in NSCLC
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Immutep
- Regulatory Clearance received for Phase 1 trial of IMP761
- Webcast to discuss data presented at ESMO Plenary Session
- Positive results in TACTI-003 for 1L HNSCC cohort B patients
- Webcast slides for new Efti clinical data in 1st line HNSCC
- Positive topline results from ph2b in head & neck cancer
Later from Immutep
- First Participant Dosed in Phase I Study of IMP761
- TACTI-003 data selected for oral presentation at ESMO 2024
- Appendix 4E & 2024 Full Year Statutory Accounts
- S&P DJI Announces September 2024 Quarterly Rebalance
- New Positive Efficacy Data for Efti in Head and Neck Cancer
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep